Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

GLP-1RAs, meanwhile, have soared in popularity as a promising intervention for obesity amid the rising burden of the chronic ...